Most benefit of RSLV-132 seen in patients with more active SLE
Treatment with RSLV-132 failed to lessen the severity and visible damage caused by skin lesions in people with systemic lupus erythematosus (SLE) in a Phase 2 clinical trial. But the experimental RNA-digesting enzyme did tend to ease general symptoms in patients with more active SLE. That’s according to data…